Part, Chapter, Paragraph
1 II, 5. 3. 7| period as well as of the generic phase. For example, many
2 II, 5. 9. 6| questionnaires, that can be generic or specific: generic tools
3 II, 5. 9. 6| be generic or specific: generic tools can be used in all
4 II, 8. 2. 1| or inability to utilise generic health services, omission
5 II, 8. 2. 1| they will increasingly seek generic health and social services
6 II, 9. 3. 1| spectrum of symptoms, from a generic loss of energy to depression,
7 III, 10. 3. 1| whole European region with generic data or parts of the European
8 III, 10. 4. 2| Providing scientific opinions on generic opinions, on generic issues
9 III, 10. 4. 2| on generic opinions, on generic issues regarding pesticide
10 IV, 11. 3. 2| such as the lowest priced generic equivalent available on
11 IV, 11. 3. 2| substitution of less expensive generic drugs for brand name drugs
12 IV, 11. 3. 2| favoured approach in Europe. Generic equivalents are less expensive
13 IV, 11. 3. 2| to dispense a lower-cost generic equivalent (e.g. in France,
14 IV, 11. 3. 2| such as substituting a generic equivalent for a branded
15 IV, 11. 3. 2| encouraged to prescribe by generic name, as in Finland, France,
16 IV, 11. 3. 2| regions in Spain. Since generic substitution is only permitted
17 IV, 11. 3. 2| above). Policies to promote generic drugs are prevalent in Europe,
18 IV, 12. 10 | campaigns for the promotion of Generic Medicines (2004&2007);~-
19 IV, 13. 6. 2| generally refer only to generic ‘beds’. It is not just the
20 IV, 13. 6. 2| countries, there is a system of generic family general practitioners,
21 IV, 13. 7. 3| three fields: biotechnology, generic tools and technologies for
22 IV, 13. 7. 3| community. In addition to generic knowledge development, for
